Prosiectau (365)
Cardiff University Schools involved in this Project
AML17: A trial of development of the Myeloid Leukaemia and high risk Myelodysplastic Syndrome in younger patients (01.08.2008 - 31.07.2014)
- Burnett, Alan
AML 17 being an acute myeloid leukaemia or high risk myelodysplastic syndrome multi-site randomised trial (01.02.2009 - 31.01.2012)
- Burnett, Alan
AML 17 Supply agreement (29.04.2009 - 15.11.2019)
- Adams, Richard
AML 18 - A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome (01.06.2013 - 31.07.2024)
- Adams, Richard
AML 18 Mylotarg charges for the following patients (01.09.2014 - 29.02.2024)
- Adams, Richard
AML 18 pilot (23.05.2011 - 22.11.2012)
- Burnett, Alan
AML 18 pilot study (08.03.2011 - 28.02.2018)
- Ottmann, Oliver
AML 18 trial (01.02.2013 - 31.01.2014)
- Hills, Robert
AML 19 (01.08.2020 - 31.10.2023)
- Adams, Richard
AML pick a winner programme (Ll-1 Trial) (10.01.2014 - 30.06.2021)
- Adams, Richard
Amplification of IL-4Ra signalling pathways in human airways through 15LO1 (01.07.2010 - 30.06.2015)
- O'Donnell, Valerie
A Muilti-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer - SCALOP-2 (01.01.2018 - 31.10.2022)
- Parry-Jones, Alison
A multi-center, open-label study evaluating the safety, tolerability and efficacy of pridopidine in patients with Huntington's disease (open PRIDE-HD) (09.05.2016 - 31.01.2018)
- Rosser, Anne
A Multicenter, Randomized, Double-blind, Placebo controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease WVE-003-001 (01.11.2021 - 30.04.2023)
- Rosser, Anne
A multicentre cluster randomised controlled trial to evaluate the effectiveness and cost-effectiveness of an environmental nutrition and physical activity intervention in nurseries NAP SACC UK (01.07.2019 - 31.10.2024)
- White, James
A multicentre cluster randomised controlled trial to evaluate the effectiveness and cost-effectiveness of a school based peer-led drug prevention intervention (The FRANK friends study) (01.03.2019 - 31.03.2024)
- White, James
A multicentre cluster randomised controlled trial to evaluate the effectiveness and cost-effectiveness of KiVa to reduce bullying in primary schools: The UK KiVa Trial (01.07.2019 - 30.09.2023)
- Townson, Julia
A multicentre, double blind, randomised, placebo-controlled, phase 3 study of indasanutlin an Mdm2 antagonist, with cytarabine versus cytarabine plus placebo in patients with relapsed or refractory acute myeloid leukaemia (01.08.2016 - 31.07.2020)
- Knapper, Steven
A multi-centre, open-label study evaluating the safety, tolerability and efficacy of Pridopidine in patients with Huntington's disease (01.07.2016 - 30.06.2018)
- Rosser, Anne
A multi centre phase 3 cluster randomized controlled trial of a manualized anger management intervention for people with mild to moderate learning disabilities attending day services (01.07.2009 - 31.05.2012)
- Hood, Kerenza
A multi-centre randomised controlled trial of a peer-volunteer led active ageing programme to prevent decline in physical function in older people at risk of mobility disability. The ACE (Active, Connected, Engagement ) study (01.09.2021 - 28.02.2025)
- Playle, Rebecca
A multicentre randomiSed controlled TRial of intraVEnous immunoglobulin (IVlg) versus standard therapy for the treatment of transverse myelitis in adults and children - STRIVE (01.09.2014 - 31.03.2019)
- Robertson, Neil
A multi-centre randomised phase 2 study of neoadjuvant chemotherapy followed by gemcitabine or cepecitabine based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer (SCALOP) (01.04.2008 - 31.01.2013)
A multicentre randomised trial of first line treatment pathways for newly diagnosed immune thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate (01.01.2017 - 31.01.2021)
- Adams, Richard
A multi country research trial called the 'BRANCH' trial - Breastfeeding counselling and management of Growth in early infancy in Asia and Africa (01.05.2023 - 31.12.2025)
- Hurt, Lisa
A Multinational trial evaluating safety and efficacy, including PK of NNC when administered for the treatment and prophylaxis of bleeding in patients with Haemophilia A (21.12.2012 - 31.03.2018)
- Collins, Peter
A multi-site, prospective, longitudinal, cohort study measuring cerebrospinal fluid-mutant Huntington protein in patients with Huntington's disease (01.03.2019 - 28.02.2021)
- Busse-Morris, Monica
An all Wales collaborative project on Ferroptosis and Tuberous Sclerosis Complex (01.04.2023 - 31.03.2025)
- Tee, Andrew
Analysis of circulation tumour DNA in translation samples from the FACTION trial (04.01.2018 - 30.06.2019)
- Jones, Robert
Analysis of cytomegalovirus pathogenesis in a human challenge system (01.04.2018 - 03.04.2023)
- Wilkinson, Gavin
Analysis of novel therapies and survival mechanisms in TSC2 deficient cells (01.12.2015 - 30.11.2017)
- Tee, Andrew
Analysis of out of scope data from the palliative and end of life care priority setting partnership with the James Lind Alliance (01.11.2015 - 07.03.2016)
- Nelson, Annmarie
Analysis of plasma arsenic levels within NCRI AML 17 trial (21.11.2011 - 30.11.2016)
- Knapper, Steven
Analysis of population data on awareness and beliefs about ovarian cancer in Wales (01.11.2011 - 31.12.2012)
- Brain, Katherine
Analysis of rapid whole genome sequencing data in a research setting to improve diagnostic yield in patients with critical illness and early-onset epilepsy. (01.04.2021 - 31.07.2024)
- Fry, Andrew
Analysis of the antiviral efficacy of Nasaleze (01.04.2021 - 30.06.2023)
- Stanton, Richard
Analysis of the burden of antibiotic resistance in E. coli associated with gut carriage and bacteraemia's in Northern India (01.09.2017 - 31.03.2018)
- Toleman, Mark
Analysis of the inhibitory effects of nitric oxide and cGMP on gap junctional communication and the EDHF phenomenon (26.06.2006 - 25.06.2009)
Analysis of urinary microRNAs as biomarkers for acute kidney injury (02.03.2015 - 30.04.2021)
- Bowen, Timothy
Analysis of urinary microRNAs as biomarkers for acute kidney injury (06.07.2015 - 16.08.2015)
- Bowen, Timothy
Analytical modelling work to inform the development of palliative care (09.02.2011 - 08.07.2011)
An analysis of wild type human cytomegalovirus (01.12.2010 - 08.05.2014)
- Wilkinson, Gavin
An anonymised dataset containing questionnaire responses from an online questionnaire with eye care practitioners in Wales (01.01.2021 - 31.12.2021)
- Nollett, Claire
An evaluation of the new medical statement "fit note": Analysis of fit note and sick note data (01.09.2011 - 01.02.2013)
- Cohen, Deborah
A new biology of clinical outcome in immune-mediated disease (01.11.2019 - 31.10.2021)
- Wong, Susan
A new window into the immune response funding during Type 1 Diabetes (01.11.2017 - 31.05.2019)
- Tatovic, Danijela
An exploratory study of the ability of 18F-FDG PET to predict response to palliative chemotherapy in patients with poor-prognosis, recurrent/metastatic head and neck cancer (01.04.2015 - 31.12.2020)
- Chester, John
An extension protocol for MS patients who participated in Genzyme-sponsored studies of alumtuzumab (01.04.2012 - 31.05.2020)
- Robertson, Neil
Angiogenesis and anti-angiogenic approach in human cancer (01.10.2007 - 30.09.2011)
- Jiang, Wen
An independent evaluation of 'The Filter' (01.07.2014 - 31.03.2015)
- Grant, Aimee
An Innovative model system of cell invasion in TSC/LAM to uncover new drug targets and therapies (15.07.2019 - 15.06.2022)
- Dunlop, Elaine
An innovative model system of cell invasion in TSL/LAM to uncover new drug targets and therapies (15.07.2019 - 14.06.2022)
- Dunlop, Elaine
An innovative multidisciplinary patient-centric early detection care model (01.04.2008 - 31.12.2009)
An integrated approach to rheumatology project (23.11.2012 - 22.11.2013)
- Cohen, Deborah
An integrated target validation and drug discovery platform for the identification of novel agents targeting genome stability for the treatment of cancer (01.09.2019 - 31.12.2021)
- Ottmann, Oliver
An investigation into the effects that CBD has in two TSC cell lines, alone and in combination with rapamycin (12.08.2018 - 30.09.2022)
- Tee, Andrew
Annual Jonathan Boulter Memorial Lecture 2017, Prof NH Ruddle (01.10.2017 - 31.01.2018)
- Caucheteux, Stephane
An observational cross-sectional study to describe the patient profile and secondary care management pathways for patients with hidradenitus in the UK (01.07.2015 - 31.07.2016)
- Ingram, John
-
- Robertson, Neil
An open label, 3-arm, randomised phase 2 study to compare the safety and efficacy of ponatinib in combination with either chemotherapy or blinatumomab (01.01.2019 - 30.06.2024)
- Ottmann, Oliver
An open-label extension study to evaluate the long-term safety and tolerability of intrathecally administered R07234292 (RG6042) in patients with Huntington's disease (BN40955) (01.10.2019 - 31.03.2023)
- Rosser, Anne
An open-label extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ISIS 443139 in Huntington's Disease patients who participated in prior investigational studies of ISIS 443139 (17.04.2018 - 30.04.2020)
- Rosser, Anne
An open label extension study to investigate the long term safety, tolerability and efficacy of PF-02545920 in subjects with Huntington's disease who previously completed study A8241021 (01.10.2015 - 31.12.2017)
- Rosser, Anne
An open label, multicentre phase 1 study to characterize the safety, tolerability, preliminary anti tumour activity, PK and MTD of Bayer 125152 in patients with advanced haematological malignancies (15.12.2016 - 15.11.2018)
- Ottmann, Oliver
An open label, multicentre, randomised, 3-arm study to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose (01.01.2014 - 31.03.2014)
- Riley, Stephen
An open prospective randomised multi-centre clinical evaluation to compare ALLEVYN gentle border with Mepilex border in the management of exuding chronic and acute wounds (22.04.2009 - 21.04.2011)
- Harding, Keith
An open randomised comparative study to evaluate the performance of aquacel extra in venous leg ulcers (01.04.2012 - 31.10.2012)
- Harding, Keith
A novel method to investigate the role of IGF-1 in the responses of human bone to mechanical loading (01.12.2015 - 30.06.2016)
- Scully, Nicole
A novel peer-support intervention using motivational interviewing for breastfeeding maintenance: A UK feasibility study (01.09.2014 - 31.01.2017)
- Paranjothy, Shantini
A novel peer-support intervention using motivational interviewing for breastfeeding maintenance: A UK feasibility study - Excess Treatment Costs (01.07.2015 - 31.03.2016)
- Paranjothy, Shantini
A novel role for oxidized lipid mediators as effectors of muscle atrophy and weakness in aging (30.09.2022 - 31.05.2027)
- O'Donnell, Valerie
A novel tool for rapid diagnosis of metastic cancer (01.07.2014 - 31.08.2015)
- Weeks, Ian
Anthropometric and metabolic correlates of sympathetic nervous system activity in young women with PCOS (01.08.2012 - 31.07.2013)
- Rees, Aled
Antibiotic duration optimisation for UTI (Optimise UTI) (01.08.2022 - 31.07.2025)
- Gillespie, David
Antibiotic resistance plasmids and their contribution to bacterial fitness and virulence (01.10.2009 - 30.09.2012)
- Walsh, Timothy
Antibiotics for lower respiratory tract infections in children presenting in primary care (ARTIC PC) (01.07.2016 - 30.06.2019)
- Francis, Nicholas
Antibiotic treatment and major bleeding in anticoagulant medication users: analysis of health record data to support safer monitoring and prescribing (01.06.2020 - 29.02.2024)
- Ahmed, Haroon
Anti-C7 monoclonal antibody (01.03.2015 - 31.08.2015)
- Morgan, Paul
Antidepressant for the prevention of DEPression following first episode Psychosis trial (ADEPP) (01.11.2019 - 31.12.2023)
- Walters, James
Antigenic ureaplasma variation and adaptation to ovineimmune response following experimental intrarauterin (01.10.2011 - 30.09.2016)
- Spiller, Brad
Anti-microbial peptides (01.12.2007 - 30.11.2008)
- Walsh, Timothy
ANti-psychotic drug Reduction in primary care for adults with learning disabilities (ANDREA-LD): A randomised double-blind placebo controlled trial (01.10.2013 - 31.12.2017)
- Kerr, Michael
Antisense peptide - PNA conjugates as novel antimicrobials for neutralising antibiotic resistance (01.01.2014 - 31.12.2016)
- Walsh, Timothy
Antisocial behaviour in young people with ADHD: Identifying risk pathways (01.03.2011 - 30.11.2013)
- Thapar, Anita
Anti-viral activity of protide derivatives of human T-cells (01.10.2015 - 31.07.2018)
- Piguet, Vincent
Antiviral capacity of surfaces (01.02.2023 - 31.01.2024)
- Stanton, Richard
A open label, multicentre, exploratory phase 2 study in INC424 for patients with primary myelofibrosis or post polycythaemia myelofibrosis or postessential thrombocythaemia myelofibrosis (08.05.2012 - 07.06.2014)
- Knapper, Steven
A pan European standardization of Legionella antibiotic susceptibility testing (01.01.2022 - 30.06.2024)
- Spiller, Brad
-
- Fegan, Christopher
-
- Burnett, Alan
A phase 1 B multi arm open label study of PDR001 and/or MGM453 in combination with decitabine in patients with acute myeloid leukaemia or high risk Myelodysplastic syndrome (14.08.2017 - 31.05.2019)
- Knapper, Steven
A phase 1b/randomised placebo controlled phase II trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor - FAKTION AZ (01.03.2014 - 30.09.2023)
- Adams, Richard
A phase 1b/randomised placebo controlled phase II trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor - FAKTION CRUK (01.10.2013 - 31.10.2019)
- Casbard, Angela
A phase 1, randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of NGM217 in adults with autoimmune diabetes (11.04.2018 - 31.03.2020)
- Dayan, Colin
A phase 1 study on the pharmacokinetics of Elacytarabine (01.01.2014 - 31.03.2014)
- Knapper, Steven
-
- Clarke, Angus
A phase 2 randomised, open label, parallel group study of the safety, tolerability, pharmacokinetics and efficacy of 2 subcutaneous dosing regimens of ATL 1103 in adult patients with acromegaly (31.05.2013 - 30.05.2014)
- Rees, Aled
A phase 2, randomised, placebo-controlled, double blind, proof of concept study of the efficacy and safety of PF-02545920 in subjects with Huntington's Disease (01.03.2015 - 31.12.2017)
- Rosser, Anne
A phase 2 randomised study to evaluate the feasibility of sequential administration of the inhibitor Ponatinib given sequentially with standard chemotherapy in younger patients aged 18-60 with acute Myeloid Leukaemia - AML 19 (01.01.2015 - 31.12.2017)
- Ottmann, Oliver
A phase 2, randomized, biomarker-driven, clinical study in patients with relapsed or refractory AML with an exploratory arm in patients with newly diagnosed high-risk AML and exploratory arms with varying levels of MCL-1 dependence (13.06.2019 - 30.06.2023)
- Knapper, Steven